Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model
Yoshinobu Ueno(Medical & Biological Laboratories (Japan)), Hiroyuki Eda(Pfizer (Japan)), Yukiko Moriguchi(Pfizer (Japan)), Sachiko Suzuki(Tsumura Research Institute (Japan)), Naoto Kato(Jichi Medical University), Mitsuko L. Yamamoto(Pfizer (Japan)), Midori Kojima(Pfizer (Japan)), Tomomi Matsuura(Keio University), Takashi Ohmi(Pfizer (Japan)), Rieko Shimozono(Pfizer (Japan))
Cited by 23
Related Papers
Distinct Metabolic Flow Enables Large-Scale Purification of Mouse and Human Pluripotent Stem Cell-Derived Cardiomyocytes
|Cell stem cell|2012|1.1k
Glutamine Oxidation Is Indispensable for Survival of Human Pluripotent Stem Cells
|Cell Metabolism|2016|252
Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway
|Nature Communications|2014|250
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
|Diabetology & Metabolic Syndrome|2017|187
A defect of LigD (human Lig4 homolog) for nonhomologous end joining significantly improves efficiency of gene-targeting in Aspergillus oryzae
|Fungal Genetics and Biology|2008|176